第二代阿尔多氨酸合成酶抑制剂用于高血压:对随机试验的贝叶斯元分析
Flavia Queiroga1, Beatriz Araújo2, André Rivera2
1Division of General Internal Medicine, Department of Medicine, Emory University, Atlanta, Georgia, USA.
JACC. Advances
|February 28, 2026
概括
第二代阿尔多合成酶抑制剂 (ASIs) 在高血压患者中有效降低血压. 然而,这些新的治疗方法增加了高血症,低血症和低血压的风险.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 第二代阿尔多合成酶抑制剂 (ASIs) 代表了管理高血压的潜在新疗法类.
- 了解这些药物的疗效和安全性,对于临床应用至关重要.
研究的目的:
- 在被诊断为高血压的患者中系统评估第二代ASI的有效性和安全性.
- 综合随机对照试验 (RCT) 的证据,为治疗准则提供信息.
主要方法:
- 对主要科学数据库进行了全面的搜索,以确定相关的RCT.
- 贝叶斯元分析模型被用来估计降血压和不良事件的治疗效果.
- 分析包括特定的ASI,如巴克斯德罗斯塔特,洛伦德罗斯塔特和维卡德罗斯塔特.
主要成果:
- 与安慰剂相比,ASIs表现出系统血压 (SBP) 和透气血压 (DBP) 显著降低.
- 虽然ASIs没有影响全因死亡率或上腺功能不充分,但它们与高血,低血和低血压的几率增加有关.
- 亚组分析表明,使用巴克斯德罗斯塔特和洛伦德罗斯塔特实现临床意义上的SBP降低的可能性很高.
结论:
- 第二代ASIs显示,在高血压患者中实现临床显著SBP降低的可能性很高.
- 使用ASI与电解质失衡 (高血,低血) 和低血压的发病率增加有关,需要对患者进行仔细监测.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Potassium-Sparing Diuretics
2.5K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.5K
Hypertension IV: Drug Therapy and Lifestyle Modifications
792
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
792


